JP4886202B2 - Relief agent for physical and / or mental discomfort before and / or during menstruation - Google Patents

Description

  The present invention relates to an agent for alleviating physical and / or mental discomfort before and / or during menstruation such as premenstrual syndrome and dysmenorrhea.

  Physical and mental discomfort before and / or during menstruation is a complaint that many premenopausal women complain of, but premenstrual syndrome (hereinafter referred to as PMS) and menstruation. Represented by difficulty.

  PMS refers to a physical symptom group or a mental symptom group that develops about one week before menstrual period (luteal phase) first reported by Frank in 1931. It is defined as “physical and psychological symptoms that start from the day before and decreases or disappears with the onset of menstruation” and is also called premenstrual tension. The typical symptoms of PMS are physical symptoms such as lower abdominal pain, lower back pain, lower abdominal tension, headache, stiff shoulders, cold limbs, increased appetite, diarrhea, constipation, swelling, painful breasts, breast swelling , Easy acne, rough skin, fatigue, sleepiness, etc. In addition, the mental symptom group includes frustrated, angry, aggressive, depressed, tearful, anxious, and the like.

  Dysmenorrhea is generally defined as something that causes abnormally strong pain or systemic damage to menstruation, and that makes it impossible to bed or work, and is also called menstrual pain. As typical symptoms of dysmenorrhea, pain such as lower abdominal pain and back pain and various physical unpleasant symptoms such as nausea, vomiting, diarrhea, and headache have been reported. It is a high disease.

  As women's advancement into society continues to increase, some scholars have pointed out the relationship between female labor productivity and PMS, and pre-menstrual and / or menstrual bodies represented by PMS and dysmenorrhea. Reducing and reducing mental and mental discomfort and improving women's quality of life (QOL) are considered to be a major social issue.

  The use of essential oils for improving various diseases and mental states is known as “aromatherapy” and has also been proposed as a method for reducing PMS and dysmenorrhea (for example, Non-Patent Document 1). . However, the benefits of aromatherapy are based on experience, and few have been scientifically confirmed to be effective or safe. Aromatherapy, as is known by methods such as massage and bathing, is generally a method of giving physical stimulation to the body while bringing essential oils into direct contact with the body. Moreover, there is a clinical trial report that fennel oil, which is one of essential oils, is effective in reducing dysmenorrhea, but this is due to oral administration (Non-patent Document 2).

In addition, it has been disclosed that β - caryophyllene is inhaled in order to improve discomfort caused by premenstrual tension, maternity blue, and menopause, but there is a demand for a substance that exhibits a higher effect (Patent Document 1). ).

Christine Westwood "Latest Aromatherapy Guidebook" Fragrance Journal, 1995, p.133-141 International Journal of Ginecolology and Obsterics (Int. J. Gynecol. Obstet.), 2003, 80 (2), p.153-7 JP 2004-339191 A

  The object of the present invention is to easily and safely relieve physical and / or mental discomfort before and / or during menstruation, especially without giving physical stimulation to the body and orally. There is to do.

The present invention volatilizes at least one fragrance selected from dodecahydro - 3a, 6,6,9a - tetramethylnaphtho [2,1-b] furan, eugenol, methyl dihydrojasmonate, and cyclopentadecanolide. In the state, for example, by inhaling during sleep, physical and / or mental discomfort is alleviated before and / or during menstruation.

  According to the present invention, physical and / or mental discomfort before menstruation and / or during menstruation can be alleviated with reproducibility by a simple means of inhaling a specific fragrance, for example, at bedtime.

Dodecahydro - 3a, 6,6,9a - tetramethylnaphtho [2,1-b] furan used in the present invention is contained in a pathological secretion amber grease produced in the body of macaque whale along with α-ambrinol. It is an aroma component and an important compound that is indispensable for amber based fragrances. When diluted, it emits a strong amber scent. Dodecahydro - 3a, 6,6,9a - tetramethylnaphtho [2,1-b] furan is commercially available under trade names such as ambroxan (Kao) and setarox (Filmenich).

Eugenol is the main component of clove oil, clove leaf oil and cinnamon leaf oil, has a strong spicy fragrance, and is widely used in fragrances and flavors.

  Methyl dihydrojasmonate is a single fragrance synthesized as a homologue of methyl jasmonate and has a jasmine-like flowery fragrance. Widely used from fine fragrances to toiletry products, and slightly used in flavors. Methyl dihydrojasmonate is commercially available under trade names such as MDJ (Kao), Edion (Firmmenich), Sepionate (Nippon Zeon).

  Cyclopentadecanolide is present in Angelica root oil and has an animal-like, musk-like sweet and strong aroma. Widely used in cosmetic fragrances because of its excellent sustainability and retention. It is one of the few blended materials for producing a natural feeling among synthetic musk. Cyclopentadecanolide is marketed under trade names such as pentalide (Iwata fragrance) and exaltolide (Filmenich).

  These fragrance | flavors may be used independently and may mix and use 2 or more types. In order to adjust the intensity of odor, dilute with odorless water or organic solvent such as triethyl citrate, dipropylene glycol, ethanol, benzyl benzoate, isopropyl myristate, diethyl phthalate, liquid paraffin, glycerin, etc. May be used. Moreover, as long as the effect of this invention is not impaired, you may mix and use for another fragrance | flavor for fragrance | flavor.

In addition, the perfume of the present invention is used as it is or in a diluted state, fibers such as cloth, nonwoven fabric and cotton, porous materials such as ceramics, silk gel, and porous cellulose particles; natural polymer materials such as gelatin, agar, and methyl cellulose are used. Water-based gels: Polyacrylic compounds, polymethacrylic acid compounds, melamine resins, urea resins and other synthetic polymer materials, wood chips, clay materials, higher fatty acid esters, higher waxes, oily materials, etc. Good.

  Furthermore, the agent for alleviating unpleasant symptoms of the present invention can be formulated or commercialized in combination with auxiliary ingredients as necessary together with the fragrance, which is an active ingredient. In addition to fragrance products such as perfumes, colons, and room fragrances, creams, emulsions, body lotions, body powders, hair creams, hair lotions, hair sprays, deodorants, sanitary products, inhalants, etc. It may be in any form such as fiber or clothing.

  The blending amount of the fragrance of the present invention in these preparations may be appropriately determined in consideration of the purpose of use and the like, and may be an amount that can sufficiently obtain an effect of alleviating unpleasant symptoms by inhalation. Although it varies depending on the use form and the selected fragrance, it is preferably 0.001 to 50% by weight, more preferably 0.001 to 30% by weight, and still more preferably 0.01 to 10% by weight. When preparing the fragrance | flavor which concerns on this invention as an indoor fragrance | flavor, it is preferable to prescribe 0.05-20 mass%.

Palliative discomfort of the invention, as volatilized flavor concentration, preferably 10~4000μg / ^{m 3,} more preferably 50~2000μg / ^{m 3,} more preferably used at 100-1000 / ^{m 3.} Moreover, it is preferable to use it while sleeping for 4 to 8 hours per day.

  Evaluating the alleviation of these symptoms by exposing the aroma during sleep for one month using a fragrance impregnated fragrance of the present invention for women complaining of PMS symptoms and letting them inhale naturally did.

That is, dodecahydro - 3a, 6,6,9a - tetramethylnaphtho [2,1-b] furan (using ambroxan), eugenol, methyl dihydrojasmonate (using MDJ) and cyclopentadecanolide (using pentalide) Is diluted with triethyl citrate, which is an unscented solvent, to the concentration shown in Table 1 so that the odor intensity is constant, and a plastic container with a lid (diameter 5 cm, height 3 cm / wide mouth bottle MC- (30 Takemoto container) was soaked in 1.5 g of cosmetic cotton in the mass shown in Table 1, distributed to the subjects as a bedroom fragrance, and used for one month. Three weeks after the start of the test, a new fragrance was used in consideration of the volatilization of the fragrance.

  The exposure time was set to bedtime in order to keep the exposure time constant between subjects. That is, a night exposure test was performed in which a container containing the fragrance of the present invention was placed on a bedside, the container was opened before going to bed, and closed when waking up.

  The test females were divided into four groups of four, each using one different fragrance at bedtime for one month, at the start of the study and at the end of the study, during the control period (one month before treatment) and A questionnaire survey was conducted on each symptom in the study period. That is, for each symptom shown in Table 2 described in the PMS memory, the score of each symptom entered by each subject in the questionnaire survey was added to obtain a PMS score, and the effect was determined. In this evaluation, the degree of each symptom was evaluated in the luteal phase, that is, from about 10 days before the start of menstruation until the start and during the menstrual period, that is, from the start of menstruation to the end of menstruation.

  PMS memory was developed by the Menstrual Liaison Council and the Japan Family Planning Association for the diagnosis of PMS, and is accompanied by a list of symptoms associated with menstruation (accompanied symptoms) that are common in Japanese women. This is a diary-type booklet created so that the subject himself records the daily symptoms and degree. The symptom list includes 25 physical symptoms (Table 2), 15 mental symptoms (Table 3), and 12 social symptoms (Table 4). Record the degree of symptom with a score of 1: no symptoms, but a little, but no effect on daily life, 2: an extent that affects everyday life, 3: abrupt).

  Table 5 shows the results of calculating the average value of the PMS scores for each group from the PMS scores of each subject and comparing the PMS scores in the control period and the test period. In any of the examples, the PMS symptom of the test subject was decreased, and the PMS score in the test period was decreased as compared with the control period, and it became clear that the fragrance of the present invention has an excellent PMS symptom mitigating effect. It was.

  In addition, Table 6 shows the results of comparison between the control period and the test period for physical symptoms, mental symptoms, and social symptoms in the PMS symptom list. In any of the examples, the PMS score of each symptom in the test period was decreased as compared with the control period, and the fragrance of the present invention not only relieves mental discomfort, but also reduces physical discomfort. It became clear to have.

  Furthermore, Table 7 shows the results of comparing the respective PMS scores in the luteal phase and menstrual phase between the control period and the test period. In any of the examples, the PMS score in the test period was decreased compared to the control period, and the fragrance of the present invention not only relieved physical and mental discomfort before menstruation (luteal phase) but also during menstruation ( It became clear that these unpleasant symptoms during the menstrual period also have an effect of relieving.

  Therefore, the fragrance of the present invention is not only effective in alleviating the symptoms of PMS, but also widely used in the premenstrual and / or menstrual periods associated with menstruation, such as symptoms of dysmenorrhea and menstrual pain complained during menstruation. And / or have been found to have the effect of alleviating mental discomfort.

  Moreover, the following impressions were mentioned from the test subject regarding the alleviation effect of the PMS symptom during the test period. In other words, as physical symptoms, such as better sleep, deep sleep, tiredness was lost, back pain was much easier, skin condition was better than usual, etc. Social symptoms such as being able to relax both physically and mentally, feeling relaxed, calming, etc., made me feel more comfortable.

Claims (4)

Menstruation which is a relieving agent for physical and / or mental discomfort before menstruation, comprising methyl dihydrojasmonate as an active ingredient, wherein the alleviation of said symptoms is caused by inhalation of volatilized methyl dihydrojasmonate Relief for previous physical and / or mental discomfort. The pre- menstrual and / or menstrual body according to claim 1, wherein methyldihydrojasmonate is carried on a carrier and is labeled to alleviate physical and / or mental discomfort before menstruation. Or a relieving agent for mental discomfort. The agent for relieving physical and / or mental discomfort before menstruation according to claim 1 and / or 2, wherein the agent is inhaled while sleeping. Physical and / or mental discomfort before menstruation, a premenstrual syndrome, relieving agent according to any one of claims 1 to 3.